Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Oleguer Pares Badell; Ricardo Zules-Oña; L.l. Armadans; Laia Pinós Tella; Blanca Borras Bermejo; Susana Isabel Otero Romero; Jose Angel Rodrigo Pendas; Martí Vivet-Escalé; Yolima Cossio-Gil; M. Antonieta Agusti Escasany; Cristina Aguilera Martin; Magdalena Campins Marti; Javier Martinez Gomez

doi:10.3390/vaccines10081217

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Oleguer Pares Badell, Ricardo Zules-Oña, L.l. Armadans, Laia Pinós Tella, Blanca Borras Bermejo, Susana Isabel Otero Romero, Jose Angel Rodrigo Pendas, Martí Vivet-Escalé, Yolima Cossio-Gil, M. Antonieta Agusti Escasany, Cristina Aguilera Martin, Magdalena Campins Marti, Javier Martinez Gomez^*

^*Corresponding author for this work

Vall d'Hebron Institute of Research (VHIR)

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.

Original language	English
Number of pages	10
Journal	Vaccines
Volume	10
Issue number	8
DOIs	https://doi.org/10.3390/vaccines10081217
Publication status	Published - 29 Jul 2022

Keywords

SARS-CoV-2
COVID-19-vaccination
Booster dose
mRNA vaccines
Adverse reactions
Health care workers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vaccines10081217

Cite this

Pares Badell, O., Zules-Oña, R., Armadans, L. L., Pinós Tella, L., Borras Bermejo, B., Otero Romero, S. I., Rodrigo Pendas, J. A., Vivet-Escalé, M., Cossio-Gil, Y., Agusti Escasany, M. A., Aguilera Martin, C., Campins Marti, M., & Martinez Gomez, J. (2022). Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination. Vaccines, 10(8). https://doi.org/10.3390/vaccines10081217

@article{27ffb86a957b4a729f68b20cb216c709,

title = "Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination",

abstract = "The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.",

keywords = "SARS-CoV-2, COVID-19-vaccination, Booster dose, mRNA vaccines, Adverse reactions, Health care workers, SARS-CoV-2, COVID-19-vaccination, Booster dose, mRNA vaccines, Adverse reactions, Health care workers, SARS-CoV-2, COVID-19-vaccination, Booster dose, mRNA vaccines, Adverse reactions, Health care workers",

author = "{Pares Badell}, Oleguer and Ricardo Zules-O{\~n}a and L.l. Armadans and {Pin{\'o}s Tella}, Laia and {Borras Bermejo}, Blanca and {Otero Romero}, {Susana Isabel} and {Rodrigo Pendas}, {Jose Angel} and Mart{\'i} Vivet-Escal{\'e} and Yolima Cossio-Gil and {Agusti Escasany}, {M. Antonieta} and {Aguilera Martin}, Cristina and {Campins Marti}, Magdalena and {Martinez Gomez}, Javier",

note = "{\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jul,

day = "29",

doi = "10.3390/vaccines10081217",

language = "English",

volume = "10",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

Pares Badell, O, Zules-Oña, R, Armadans, LL, Pinós Tella, L, Borras Bermejo, B , Otero Romero, SI, Rodrigo Pendas, JA, Vivet-Escalé, M, Cossio-Gil, Y, Agusti Escasany, MA, Aguilera Martin, C, Campins Marti, M & Martinez Gomez, J 2022, 'Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination', Vaccines, vol. 10, no. 8. https://doi.org/10.3390/vaccines10081217

TY - JOUR

T1 - Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

AU - Pares Badell, Oleguer

AU - Zules-Oña, Ricardo

AU - Armadans, L.l.

AU - Pinós Tella, Laia

AU - Borras Bermejo, Blanca

AU - Otero Romero, Susana Isabel

AU - Rodrigo Pendas, Jose Angel

AU - Vivet-Escalé, Martí

AU - Cossio-Gil, Yolima

AU - Agusti Escasany, M. Antonieta

AU - Aguilera Martin, Cristina

AU - Campins Marti, Magdalena

AU - Martinez Gomez, Javier

PY - 2022/7/29

Y1 - 2022/7/29

N2 - The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.

AB - The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.

KW - SARS-CoV-2

KW - COVID-19-vaccination

KW - Booster dose

KW - mRNA vaccines

KW - Adverse reactions

KW - Health care workers

KW - SARS-CoV-2

KW - COVID-19-vaccination

KW - Booster dose

KW - mRNA vaccines

KW - Adverse reactions

KW - Health care workers

KW - SARS-CoV-2

KW - COVID-19-vaccination

KW - Booster dose

KW - mRNA vaccines

KW - Adverse reactions

KW - Health care workers

U2 - 10.3390/vaccines10081217

DO - 10.3390/vaccines10081217

M3 - Article

C2 - 36016105

SN - 2076-393X

VL - 10

JO - Vaccines

JF - Vaccines

IS - 8

ER -

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this